Aspen Aerogels, Inc. (NYSE:ASPN – Get Free Report) has been assigned an average recommendation of “Hold” from the six brokerages that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $5.1875.
A number of research firms have recently commented on ASPN. Roth Mkm reissued a “buy” rating and set a $5.75 target price on shares of Aspen Aerogels in a research note on Friday, May 8th. Barclays boosted their price objective on Aspen Aerogels from $3.00 to $4.00 and gave the stock an “underweight” rating in a research note on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aspen Aerogels in a report on Wednesday, June 24th. Finally, Wall Street Zen upgraded Aspen Aerogels from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th.
Read Our Latest Analysis on ASPN
Institutional Investors Weigh In On Aspen Aerogels
Aspen Aerogels Stock Performance
Shares of NYSE:ASPN opened at $5.58 on Monday. The business’s 50 day moving average price is $5.44 and its 200-day moving average price is $4.07. Aspen Aerogels has a 1 year low of $2.30 and a 1 year high of $9.78. The firm has a market capitalization of $462.47 million, a price-to-earnings ratio of -4.10 and a beta of 2.98. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.89 and a quick ratio of 2.54.
Aspen Aerogels (NYSE:ASPN – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The construction company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.01). The company had revenue of $37.88 million during the quarter, compared to analysts’ expectations of $36.58 million. Aspen Aerogels had a negative return on equity of 22.16% and a negative net margin of 48.64%.Aspen Aerogels’s revenue was down 51.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.06) EPS. Aspen Aerogels has set its Q2 2026 guidance at -0.240–0.17 EPS. On average, equities research analysts forecast that Aspen Aerogels will post -0.8 earnings per share for the current fiscal year.
About Aspen Aerogels
Aspen Aerogels, Inc, headquartered in Northborough, Massachusetts, develops and manufactures high-performance aerogel insulation materials and custom engineered solutions. Founded in 2001 as a spin-out from Department of Energy research, the company pursued an initial public offering on the NYSE in 2014 under the ticker ASPN. Aspen Aerogels combines proprietary aerogel formulations with advanced manufacturing processes to deliver products known for their low thermal conductivity, lightweight construction and robust mechanical properties.
The company’s product portfolio spans blanket insulation, boards, and custom shapes built around several proprietary brands, including Pyrogel, Cryogel and Spaceloft.
Featured Articles
- Five stocks we like better than Aspen Aerogels
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for Aspen Aerogels Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Aerogels and related companies with MarketBeat.com's FREE daily email newsletter.
